Blueprint Medicines (STU:2L9) Tax Provision : €-1.1 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Blueprint Medicines Tax Provision?

Blueprint Medicines's tax provision for the three months ended in Dec. 2024 was €-0.6 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.1 Mil.

Blueprint Medicines Tax Provision Historical Data

The historical data trend for Blueprint Medicines's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Tax Provision Chart

Blueprint Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

-0.87

-2.66

-4.94

-0.89

-1.17

Blueprint Medicines Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-0.06	-0.17	-0.10	-0.25	-0.64

Blueprint Medicines Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.1 Mil.

Blueprint Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (STU:2L9) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

BPMC:USA 0HOJ:UK 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines